Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis

Last updated: September 25, 2023
Sponsor: Flemming Bendtsen
Overall Status: Active - Recruiting

Phase

4

Condition

Colic

Inflammatory Bowel Disease

Crohn's Disease

Treatment

Mesalazine

Clinical Study ID

NCT04133194
1337-EASI-trial
  • Ages 18-60
  • All Genders

Study Summary

Several oral mesalazine (5-ASA) formulations exist, but the regimes require several tablets per day. Such regimens are not ideal and can interfere with normal daily activities of patients. Non-adherence has been associated with an increase in the risk of relapse and worse disease course; leading to a decrease in quality of life, an increase in societal and personal costs, and worst case increases the risk of colorectal cancer. Recently, a new formula for 5-ASA has been approved by the Danish Medicine Agency, with a single tablet regime per day.

Primary purpose:

• To investigate whether a simplified treatment regimen for 5- ASA (1600 mg as one tablet per day [intervention]) improves adherence with preserved remission rates compared to conventional therapy.

Secondary purposes:

  • Compare levels of endoscopic, mucosal and histological inflammation in predicting risk of relapse between the intervention group and the conventional therapy group.

  • Investigate whether a simplified treatment regimen improves the disease course compared to the conventional therapy.

  • To assess the correlation between different endpoints and the disease courses, with the use of clinical, endoscopic, histological, self-reported and biochemical markers.

  • Improve, correlate and assess patient-reported outcomes in a prospective manner.

  • To establish a biobank of cases with quiescent/mild ulcerative colitis (UC) for identification of future biomarkers.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Signed informed consent
  • Age between and including 18 and 60
  • Diagnosed with UC according to the Copenhagen Diagnostic Criteria
  • Length of disease of max. 10 years
  • Stable remission on 5-ASA (defined as partial Mayo score ≤1) for at least 2 monthswithout need for oral corticosteroids before inclusion.
  • Endoscopic remission defined as Mayo Clinic Endoscopic Score < 2
  • Have had a relapse within the last 2 years
  • Defined as the need of escalation of treatment or change medical treatment.

Exclusion

Exclusion Criteria:

  • Evidence of infectious diarrhoea (i.e. pathogenic viruses, bacteria or Clostridiumdifficile toxin in stool culture) within the last month
  • On immunomodulators, including methotrexate
  • On any biological therapy
  • Any previous abdominal surgery related to UC
  • Any chronic infections (e.g. HBV, HCV, HIV)
  • Any severe concomitant cardiovascular, autoimmune, hematologic, hepatic, renal,endocrine, oncologic or psychiatric disorder, which in the opinion of the investigatormight have an influence on the patient's compliance or the interpretation of theresults
  • Well-founded doubt about the patient's cooperation, e.g., because of addiction toalcohol or drugs in the opinion of the investigators.
  • Participation in another clinical trial within the last 30 days, or simultaneousparticipation in another clinical trial.
  • Any previous documented allergic reaction to tested the medical drugs

Study Design

Total Participants: 200
Treatment Group(s): 1
Primary Treatment: Mesalazine
Phase: 4
Study Start date:
November 28, 2019
Estimated Completion Date:
March 01, 2025

Connect with a study center

  • Copenhagen University Hospital Hvidovre

    Hvidovre, 2200
    Denmark

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.